I

t’s been a good month for companies developing the experimental immunotherapies known as CAR-T, as several released data showing strong results in patients with blood cancers.  Now, though, they face a new challenge: Proving they can actually manufacture the highly personalized treatments quickly and efficiently — and get them to cancer patients across the country. 

And hidden in some of the positive data are hints that such turnarounds will be tough.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy